KRAZATI (adagrasib) is an oral targeted therapy indicated for treating adult patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), aiming to inhibit tumor growth by targeting the KRAS G12C mutation.

Therapeutic Effect of KRAZATI (Adagrasib) in KRAS G12C-Mutated Non-Small Cell Lung Cancer

KRAZATI (adagrasib) is an oral selective inhibitor of the KRAS G12C mutation, primarily indicated for adult patients with non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation. By specifically targeting and inhibiting the KRAS G12C mutation, KRAZATI disrupts downstream signaling pathways crucial for tumor cell survival and proliferation, leading to tumor regression. Clinical trials have demonstrated its efficacy as a single-agent treatment, with patients showing significant clinical benefit and disease control. This therapeutic approach offers a promising option for patients with limited treatment alternatives, addressing a previously untargeted mutation in NSCLC.